However, the VHVs have generally engaged in blood-stage treatment of vivax malaria, and have not been allowed to prescribe PQ because of safety concerns about severe acute haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient patients. Here, G6PD is linked to non-autoimmune hemolytic anemia.